C4 Therapeutics Makes Auspicious Debut With Roche Tie-Up, $73m Series A
This article was originally published in The Pink Sheet Daily
On the strength of research licensed from Dana-Farber Cancer Institute, C4 will develop targeted protein degradation therapeutics against disease-causing proteins in a range of therapeutic areas that could include cancer and the central nervous system.
You may also be interested in...
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.